A phase I study of XL281, a selective oral RAF kinase inhibitor, in patients (Pts) with advanced solid tumors Meeting Abstract


Authors: Schwartz, G. K.; Robertson, S.; Shen, A.; Wang, E.; Pace, L.; Dials, H.; Mendelson, D.; Shannon, P.; Gordon, M.
Abstract Title: A phase I study of XL281, a selective oral RAF kinase inhibitor, in patients (Pts) with advanced solid tumors
Meeting Title: 45th Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title: Journal of Clinical Oncology
Volume: 27
Issue: 15 Suppl.
Meeting Dates: 2009 May 29-Jun 2
Meeting Location: Orlando, FL
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2009-05-20
Start Page: 149s
Language: English
ACCESSION: WOS:000276606602403
PROVIDER: wos
DOI: 10.1200/jco.2009.27.15_suppl.3513
Notes: Meeting Abstract: 3513 -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Gary Schwartz
    385 Schwartz
  2. Heather J Dials
    9 Dials
  3. Latisha Pace
    3 Pace